BlackRock Amends Fulgent Genetics Stake as of Dec 31, 2023
Ticker: FLGT · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1674930
| Field | Detail |
|---|---|
| Company | Fulgent Genetics, Inc. (FLGT) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its passive stake in Fulgent Genetics, signaling a portfolio adjustment.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating a change in their ownership stake in Fulgent Genetics, Inc. as of December 31, 2023. This update, an Amendment No. 2, shows BlackRock's adjusted passive investment in the medical laboratories company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in Fulgent Genetics' future prospects, potentially influencing other investors' decisions.
Why It Matters
Changes in large institutional ownership, like BlackRock's, can impact investor sentiment and stock price due to their perceived market influence and research capabilities.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should monitor subsequent filings from BlackRock or other major institutions for Fulgent Genetics to identify any significant shifts in ownership that could signal a change in their investment thesis.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Fulgent Genetics, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring this filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 2 (number) — the specific amendment number for this filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 2)' sections.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What is the subject company of this filing?
The subject company is Fulgent Genetics, Inc., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Fulgent Genetics, Inc.' and 'Name of Issuer: Fulgent Genetics, Inc.'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Fulgent Genetics, Inc. (FLGT).